Skip to content
Datasets/PDC000245

CPTAC GBM Discovery Study

Underused opportunityOpenMachine-extracted
Clinical Proteomic Tumor Analysis ConsortiumAvailable from PDC

Can it answer your research question?

4 of 6 supported
  • Overall survival

    Supported

    Vital status and time are populated; median follow-up 1.1 years; 100 cases with follow-up; endpoints: overall survival, recurrence-free interval.API

  • Progression or recurrence

    Supported

    A time to event is derivable: recurrence-free interval; progression_or_recurrence is informative for 0% of cases.API

  • Treatment response

    Supported

    treatment_outcome is populated for 0.9% of cases; criteria: Persistent Disease.API

  • Which drug was given

    Not supported

    therapeutic_agents is recorded for no case in the harmonized records.API

  • Stage-adjusted modelling

    Not supported

    ajcc_pathologic_stage is informative for no case in the harmonized records.API

  • Analysis by race or ethnicity

    Supported

    Race is informative for 97% of cases.API

Judged from the repository’s own field completeness (thresholds). “Not measured” means we have not probed that field for this record, not that the data lack it.

At a glance

Every percentage is the repository’s own record of what is filled in
CasesAPI
111
Measurement types
5
Follow-upAPI
12.8 months
for 100 of 111 cases; overall survival, recurrence-free interval
Treatment responseAPI
Recorded
Persistent Disease

SubjectCALC

Brain and central nervous system

As filed by the repository

GlioblastomaBrain

Who is in the cohortAPI

A usable value“Not reported” or “unknown”No value recorded
  • Sex61 male · 49 female · 1 not reported
  • Race57 white · 30 asian · 21 other · 2 not reported · 1 Unknown
  • Ethnicity31 not hispanic or latino · 4 hispanic or latino · 76 not reported
  • Vital status83 Dead · 27 Alive · 1 Not Reported

What was measured, and on how many

5 measurement types, 3 covering the whole cohort.

  • Acetylome mass spectrometry (TMT11 / DDA)scarce111 of 111 · 100%
  • Lipidome mass spectrometry (Label Free / DDA)scarce83 of 111 · 75%
  • Metabolome mass spectrometry (Label Free / N/A)scarce83 of 111 · 75%
  • Phosphoproteome mass spectrometry (TMT11 / DDA)111 of 111 · 100%
  • Proteome mass spectrometry (TMT11 / DDA)111 of 111 · 100%
Platform, files and data levels
AssayPlatformFilesLevels
Acetylome mass spectrometry (TMT11 / DDA)APITMT11-raw, peptide/protein matrix
Lipidome mass spectrometry (Label Free / DDA)APILabel Free-raw, peptide/protein matrix
Metabolome mass spectrometry (Label Free / N/A)APILabel Free-raw, peptide/protein matrix
Phosphoproteome mass spectrometry (TMT11 / DDA)APITMT11-raw, peptide/protein matrix
Proteome mass spectrometry (TMT11 / DDA)APITMT11-raw, peptide/protein matrix
How complete all 27 clinical fields are - 8 informative for at least 80% of cases

A field counts as informative only when it holds a real value. “Not reported” blocks an analysis just as a missing field does. Fields marked 1:n can hold several records per case, so they show the share of cases with any record.

Informative - a usable valuePresent but uninformative - “not reported” or “unknown”Absent - no value recorded

Outcome

  • Vital statusAPI>99%
  • Days to deathAPI66%
  • Cause of deathAPI65%
  • Days to recurrenceAPI26%
  • Progression or recurrenceAPI0%
  • Last known disease statusAPI0%

Follow-up

  • Days to last follow-upAPI90%

Treatment

  • Treatment typeAPI<1%
  • Treatment outcomeAPI<1%
  • Prior treatmentAPI0%
  • Therapeutic agentsAPI0%
  • Regimen or line of therapyAPI0%
  • Treatment givenAPI0%

Staging

  • AJCC pathologic stageAPI0%
  • AJCC clinical stageAPI0%
  • AJCC pathologic stage (tumor_stage)API0%

Diagnosis

  • Primary diagnosisAPI90%
  • Tissue or organ of originAPI90%
  • Prior malignancyAPI0%
  • Synchronous malignancyAPI0%

Pathology

  • Morphology (ICD-O)API90%
  • Tumor gradeAPI0%
  • Classification of tumorAPI0%

Demographics

  • Sex at birth (gender)API>99%
  • Age at diagnosisAPI>99%
  • RaceAPI97%
  • EthnicityAPI32%

Access

OpenDownload without an account.API

Direct download from the PDC portal or its API; no account required

Open components
5 analytical fraction studies
License
Open access under the PDC data use terms
Citation requirement
Cite the PDC study identifier and the study's primary publication; PDC asks that the consortium be acknowledged.

What it is good for

Written and checked by a reviewer, not generated from metadata.

No reviewed research questions yet. The measurements and field completeness above are machine-extracted and still useful for judging fit.

What it cannot tell you

Written by a reviewer against the source, not inferred from what is missing.

No reviewed limitations yet. Check the field completeness chart above before committing to an analysis. Low coverage on an endpoint you need is the most common blocker.

Who has used it

Articles that analyzed these data, counted separately from articles that only cited the paper. Only the first counts as reuse.

Analyzed the dataCALC2
1
accession in the methods section
Declared using it
0
named in a data availability statement
Cited the paper
-
attention to the publication, not reuse of the data
Against expectation
Well below
about 7 articles expected; index -2.04

What articles did with it

Only the last row counts as reuse. Where the accession appears in an article tells us what the authors did with the data.

  • Mentioned the dataset0
  • Accession found in text0
  • Declared using it0
  • Analyzed the data1

Against comparable datasets

1 article analyzed these data. About 7 would be expected. The expectation comes from a model of size, age, breadth and access tier.

  • Analyzed it1
  • Expected~7
More articles are listed below than the count
The headline count is deliberately narrow: one section of one accession (METHODS:"PDC000245"), so every dataset in the corpus is counted the same way and the numbers can be compared. The 3 articles listed below were retrieved and graded one at a time, and an article counts as having analyzed the data wherever the accession sits in the analysis - methods, results, tables, figures or supplement - under any of this dataset’s accessions. Read the list as the evidence about these articles, and the count as the number that is comparable across datasets.
Why this is an underused opportunity
  • 1 article(s) reference this dataset's accession in a methods section, against 7.2 predicted for datasets of comparable size, age, modality breadth and access tier (reuse gap index -2.04 on a log2 scale, 11th percentile of the assessed corpus).

Compared against 132 datasets in this corpus with a citable accession and sufficient metadata. See Methods for the model.

Articles that analyzed the data

Each was retrieved and graded individually.

Deep-review sample: author overlap and funding were checked only for the 4 articles listed here, not for every article examined. Of the 3 that analyzed the data, author overlap with the generating team could not be checked for any of them, and 1 of the 3 we could check were themselves NCI-funded. These are sample counts, not population estimates.

1 article with weaker evidence

These name the dataset, but we could not confirm the data were analyzed. Shown for completeness and not counted as reuse.

Community examples

Share your example

Analyses someone ran on these data end to end, each with a receipt recording when it ran, against which packages and for how long.

Nobody has shared an analysis of this dataset yet. The examples on other datasets cover the common patterns and can be adapted - and if you adapt one, it belongs here.

Start here

Starter code generated from this record’s own identifiers, then the access steps.

Get the data in code

PDC: file manifest through the GraphQL APIpython

This cohort spans 5 PDC studies (PDC000245, PDC000553, PDC000552, PDC000205, PDC000204). Repeat for each.

import requests

PDC_STUDY = "PDC000245"
API = "https://proteomic.datacommons.cancer.gov/graphql"

def gql(query, **variables):
    r = requests.post(API, json={"query": query, "variables": variables}, timeout=180)
    r.raise_for_status()
    body = r.json()
    if body.get("errors"):
        raise RuntimeError(body["errors"][0]["message"])
    return body["data"]

# filesPerStudy only fills its fields when given the study UUID: called with the
# pdc_study_id it returns the right number of rows with every column null.
study = gql("""query ($id: String!) {
  study(pdc_study_id: $id acceptDUA: true) { study_id study_name }
}""", id=PDC_STUDY)["study"][0]

files = gql("""query ($sid: String!) {
  filesPerStudy(study_id: $sid acceptDUA: true) {
    file_id file_name file_type data_category md5sum file_size signedUrl { url }
  }
}""", sid=study["study_id"])["filesPerStudy"]

print(study["study_name"], "-", len(files), "files")
for f in files[:3]:
    print(f["file_name"], f["data_category"], f["file_size"])
# Each signedUrl.url is a time-limited download link; stream it to disk with requests.get(url, stream=True).
This page as data: limitations firstbash
curl -s https://cd2s.vercel.app/data/datasets/pdc-cptac-gbm-discovery-study.json | python3 -c '
import json, sys
r = json.load(sys.stdin)
for l in r["limitations"]:
    print(l["severity"].upper(), "-", l["statement"][:120])
print("survival endpoint:", r["longitudinal"]["has_survival_endpoint"], "| treatment response:", r["longitudinal"]["has_treatment_response"])'

Access steps

  1. 1
    Open the study in the PDC portalFor people5 minutes

    Proteomic data are released open; the portal's use guidelines still apply. This record spans 5 PDC studies; repeat for each.

    https://pdc.cancer.gov/pdc/study/PDC000245

    Generated from repository policy. Check the linked policy before downloading.

  2. 2
    Accept the data use guidelines and downloadFor peopleminutes to hours, by study size

    The portal asks for acknowledgement and citation, not a data access request.

    https://pdc.cancer.gov/pdc/data-use-guidelines

    Generated from repository policy. Check the linked policy before downloading.

  3. 3
    Resolve the study UUID, then fetch the file manifestFor agents

    filesPerStudy keys on the study UUID, not on PDC000245: called with the pdc_study_id it returns the right number of rows with every column null. Resolve the UUID first and pass the terms acknowledgement.

    python - <<'PY'
    import requests
    API = "https://proteomic.datacommons.cancer.gov/graphql"
    
    def gql(query, **variables):
        r = requests.post(API, json={"query": query, "variables": variables}, timeout=180)
        r.raise_for_status()
        body = r.json()
        if body.get("errors"):
            raise RuntimeError(body["errors"][0]["message"])
        return body["data"]
    
    study = gql('query($id:String!){ study(pdc_study_id:$id acceptDUA:true){ study_id } }',
                id="PDC000245")["study"][0]
    files = gql('query($sid:String!){ filesPerStudy(study_id:$sid acceptDUA:true)'
                '{ file_id file_name file_size } }', sid=study["study_id"])["filesPerStudy"]
    print(len(files), "files")
    PY
    https://pdc.cancer.gov/data-dictionary/publicapi-documentation/

    Generated from repository policy. Check the linked policy before downloading.

Provenance

All of it, and more, is in this record’s JSON.

Identifiers

Versions and verification

Released
1 Jan 2025
Metadata retrieved
18 Sept 2026
Review status
Machine-extracted
Data generation funding
Funded data generation

Funding

Awards resolved through NIH RePORTER. Awards that paid to generate these data are listed apart from awards that paid to reuse them. Both are returns on NCI investment, but different ones.

Funded reuse of these data

  • U19CA264504Small molecule inhibitors with a therapeutic window for EGFR signaling variants in glioblastomaMICHAEL J ECK, Tracy T BatchelorFY2021-2025API
  • R35CA220449Human metabolic variation as a window into cancer initiation and progressionRALPH J DEBERARDINISFY2017-2026API
  • R01CA289260Metabolic mechanisms of glioma progressionKalil G Abdullah, Samuel Kent McBrayerFY2025-2026API
  • R01CA258586Exploiting Pyrimidine Nucleotide Synthesis Dependence for IDH Mutant Glioma TherapyKalil G Abdullah, Samuel Kent McBrayerFY2021-2025API
  • K99CA277576Defining mechanisms of metabolic-epigenetic crosstalk that drive glioma initiationYi XiaoFY2023-2024API
  • F30CA271634Dissecting Mechanisms of Pyrimidine Synthesis Dependence in IDH Mutant GliomaMilan Rashmin SavaniFY2022-2025API

Funded infrastructure or harmonization

  • P50CA165962Project 1: Targeted therapeutics for pediatric low-grade gliomaBenjamin Harris Kann, DAPHNE A. HAAS-KOGANFY2013-2026API

For softwarerecord JSON